2016 was not a good year for new medicines. The U.S. Food and Drug Administration cleared just 22 new drugs for sale last year, the lowest number since 2010 and a sharp decline from 2015's total of 45 approved drugs. While the FDA simply delayed approval on some applications that will likely be given the green light in 2017, there's also been a decline in applications overall, Reuters reports. Despite recent advances in cancer treatment and other genetic diseases, drug companies are finding difficulty securing financial returns due to political pushback against the rising costs of medicine. Returns on research and development investment at the top 12 pharmaceutical companies fell to 3.7 percent in 2016, from a high of 10.1 percent in 2010.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
-
'Miscarriage of justice'Today's Newspapers A roundup of the headlines from the US front pages
-
Inside Marseille's deadly drug warsThe Explainer Teenage hitmen recruited through social media are lured by money and gang 'brand'
-
A human foot found on Mount Everest is renewing the peak's biggest mysteryThe discovery is reviving questions about who may have summited the mountain first
-
Ports reopen after dockworkers halt strikeSpeed Read The 36 ports that closed this week, from Maine to Texas, will start reopening today
-
Empty-nest boomers aren't selling their big homesSpeed Read Most Americans 60 and older do not intend to move, according to a recent survey
-
Brazil accuses Musk of 'disinformation campaign'Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
-
Disney board fends off Peltz infiltration bidSpeed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
-
Disney and DeSantis reach detenteSpeed Read The Florida governor and Disney settle a yearslong litigation over control of the tourism district
-
Visa and Mastercard agree to lower swipe feesSpeed Read The companies will cap the fees they charge businesses when customers use their credit cards
-
Reddit IPO values social media site at $6.4 billionSpeed Read The company makes its public debut on the New York Stock Exchange
-
Housing costs: the root of US economic malaise?speed read Many voters are troubled by the housing affordability crisis
